Sunday |
4:00 pm - 8:00 pm | Arrival and Check-in |
6:00 pm | Dinner |
7:30 pm - 7:40 pm | Welcome / Introductory Comments by GRC Site Staff |
7:40 pm - 9:30 pm | Keynote Session: The Role of Government in Enabling New Antibacterial Discovery and Development |
| Discussion Leaders: Heike Broetz-Oesterhelt (Institute for Microbiology and Infection Medicine, University of Tübingen, Germany) and Jennifer Leeds (Novartis Institutes for BioMedical Research, USA) |
7:40 pm - 7:55 pm | Opening Remarks |
7:55 pm - 8:00 pm | Introduction by Discussion Leader |
8:00 pm - 8:35 pm | Sally Davies (U.K. Department of Health, United Kingdom) "Global Policy in Antimicrobial Resistance (AMR)" |
8:35 pm - 8:45 pm | Discussion |
8:45 pm - 9:20 pm | Sumathi Nambiar (U.S. Food and Drug Administration, USA) "FDA Perspective on Antibacterial Drug Development" |
9:20 pm - 9:30 pm | Discussion |
Monday |
7:30 am - 8:30 am | Breakfast |
9:00 am - 12:30 pm | New Antibacterial Targets: Focusing on Likelihood of Success |
| This session will focus on which new targets deserve our attention, and why are they more likely to enable successful drugs. |
| Discussion Leader: Hans-Georg Sahl (University of Bonn, Germany) |
9:00 am - 9:05 am | Introduction by Discussion Leader |
9:05 am - 9:40 am | Sarah McLeod (Entasis Therapeutics, USA) "Small Molecule Inhibitors of Gram-Negative Lipoprotein Trafficking Discovered by Phenotypic Screening" |
9:40 am - 9:50 am | Discussion |
9:50 am - 10:25 am | Tanja Schneider (University of Bonn, Germany) "Targeting Bactoprenol-Bound Cell Envelope Precursors" |
10:25 am - 10:35 am | Discussion |
10:35 am - 11:00 am | Coffee Break |
11:00 am - 11:35 am | Sarah Ades (Pennsylvania State University, USA) "Targeting Stress: Identifying Inhibitors of SigmaE-Hfq-sRNA Virulence Pathway" |
11:35 am - 11:45 am | Discussion |
11:45 am - 12:20 pm | Rolf Mueller (Helmholtz-Institute for Pharmaceutical Research Saarland, Germany) "Natural Product Research Towards Innovative Antibacterial Target-Compound Pairs: Challenges and Opportunities" |
12:20 pm - 12:30 pm | Discussion |
12:30 pm | Lunch |
1:30 pm - 4:30 pm | Free Time |
4:30 pm - 6:00 pm | Poster Session |
6:00 pm - 8:00 pm | Technologies to Enable Antibacterial Discovery and Development |
| This session will focus on what technologies are necessary to bring new compounds against novel targets to the clinic, and where are the innovative approaches to doing so. |
| Discussion Leader: Terry Roemer (Merck Infectious Disease Research, USA) |
6:00 pm - 6:05 pm | Introduction by Discussion Leader |
6:05 pm - 6:30 pm | Domingo Gargallo-Viola (ABAC Therapeutics, Spain) "Use of the PasNas Platform to Enable High Quality Antibacterial Hit Finding" |
6:30 pm - 6:40 pm | Discussion |
6:40 pm - 7:10 pm | Mariana Pinho (Instituto de Tecnologia Quimica e Biologica, Portugal) "Studying Antibiotic Mechanisms of Action at the Single Cell Level" |
7:10 pm - 7:20 pm | Discussion |
7:20 pm - 7:50 pm | Joe Pogliano (University of California, San Diego, USA) "Bacterial Cytological Profiling: A New Platform for Antibiotic Discovery" |
7:50 pm - 8:00 pm | Discussion |
8:00 pm | Dinner |
Tuesday |
7:30 am - 8:30 am | Breakfast |
8:30 am | Group Photo |
9:00 am - 12:30 pm | Identifying High-Value Chemical Starting Points: Hit Finding Revisited |
| This session will focus on what defines a high value chemical starting point and where do those come from. Speakers will offer detailed examples to demonstrate how these have enabled/will enable antibacterial drug discovery. |
| Discussion Leader: Michael Barbachyn (Calvin College, USA) |
9:00 am - 9:05 am | Introduction by Discussion Leader |
9:05 am - 9:35 am | Folkert Reck (Novartis Institutes for Biomedical Research, USA) "Chemical Property Space – Considerations for Antibacterial Drug Discovery" |
9:35 am - 9:45 am | Discussion |
9:45 am - 10:15 am | Christina Spry (The Australian National University, Australia) "Fragment-Based Approaches to Antibacterial Lead Discovery: Targeting Coenzyme A Biosynthesis in Mycobacterium tuberculosis" |
10:15 am - 10:25 am | Discussion |
10:25 am - 10:55 am | Coffee Break |
10:55 am - 11:25 am | Olga Genilloud (Fundación MEDINA, Spain) "Discovering High Value Hits from Microbial Natural Products" |
11:25 am - 11:35 am | Discussion |
11:35 am - 12:05 pm | Matthew Cooper (The University of Queensland, Australia) "Chemical Diversity in Screening Libraries for Antibiotic Action: Academic Collections vs. Commercial Libraries" |
12:05 pm - 12:15 pm | Discussion |
12:15 pm - 12:25 pm | Bradley Poulsen (Massachussetts General Hospital / Broad Institute, Harvard Medical School, USA) "A Multiplexed Chemical Screen of Pseudomonas aeruginosa Hypomorphs Rapidly Identifies Novel Antibiotic Leads" |
12:25 pm - 12:30 pm | Discussion |
12:30 pm | Lunch |
1:30 pm - 4:30 pm | Free Time |
4:30 pm - 6:00 pm | Poster Session |
6:00 pm - 8:00 pm | Addressing the Gap Between In Vitro (Target) and In Vivo (Cellular) Potency: Strategies to Enable the Latter |
| This session will focus on strategies to narrow the gap between target and cellular potency, which is a particular challenge in certain types of bacteria such as Gram negatives and TB. |
| Discussion Leader: Charles Dean (Novartis Intitutes for Biomedical Research, USA) |
6:00 pm - 6:05 pm | Introduction by Discussion Leader |
6:05 pm - 6:35 pm | Athanasios Typas (European Molecular Biology Laboratory, Germany) "Combinatorial Drug Treatments: From Drug Repurposing to Discovering General Design Principles and Underlying Mechanisms" |
6:35 pm - 6:45 pm | Discussion |
6:45 pm - 7:10 pm | Paolo Ruggerone (University of Cagliari, Italy) "Membrane Barrier in Drug Resistance: Microscopic Insights into Influx and Efflux Combinations" |
7:10 pm - 7:20 pm | Discussion |
7:20 pm - 7:50 pm | Olga Lomovskaya (The Medicines Company, USA) "Discovery of Novel Broad-Spectrum Carbapenemase Inhibitors: Challenges and Opportunities" |
7:50 pm - 8:00 pm | Discussion |
8:00 pm | Dinner |
Wednesday |
7:30 am - 8:30 am | Breakfast |
9:00 am - 12:30 pm | Learning from Clinical Experience with Validated Targets |
| This session will focus on the challenges and opportunities associated with drugs against clinically-precedented antibacterial targets. Examples will provide a learning experience for the community. |
| Discussion Leader: Michael Dudley (The Medicines Company, USA) |
9:00 am - 9:05 am | Introduction by Discussion Leader |
9:05 am - 9:40 am | Seamus O'Brien (AstraZeneca, United Kingdom) "Envisioning the Path from Idea to Registration: Lessons from Recent Antibacterial Development Programs" |
9:40 am - 9:50 am | Discussion |
9:50 am - 10:25 am | Mary Motyl (Merck Sharp & Dohme Corp., USA) "Learnings from Planning a Phase 3 Trial of Imipenem/Relebactam Against Imipenem-Resistant Gram Negative Rods" |
10:25 am - 10:35 am | Discussion |
10:35 am - 11:05 am | Coffee Break |
11:05 am - 11:40 am | Jacques Dumas (Tetraphase Pharmaceuticals, Inc., USA) "Learnings from Planning Global Trials with Eravacycline" |
11:40 am - 11:50 am | Discussion |
11:50 am - 12:20 pm | Daniel Ritz (Actelion Pharmaceuticals Ltd, Switzerland) "Unique Aspects of Cadezolid, a Novel Quinolonyl-Oxazolidinone in Development for Treatment of C. difficile Infections" |
12:20 pm - 12:30 pm | Discussion |
12:30 pm | Lunch |
1:30 pm - 4:30 pm | Free Time |
4:30 pm - 6:00 pm | Poster Session |
6:00 pm - 8:00 pm | Learning from Clinical Experience with Novel Targets |
| This session will focus on the challenges and opportunities associated
with drugs against clinically-unprecedented antibacterial targets. Examples
will provide a learning experience for the community. |
| Discussion Leader: Ursula Theuretzbacher (Center for Anti-Infective Agents, Austria) |
6:00 pm - 6:05 pm | Introduction by Discussion Leader |
6:05 pm - 6:35 pm | Antonio DiGiandomenico (MedImmune, LLC, USA) "MEDI3902: A Novel Multi-Mechanistic Bispecific
Antibody for Prevention of Pneumonia in Ventilated Patients Caused by Pseudomonas
aeruginosa" |
6:35 pm - 6:45 pm | Discussion |
6:45 pm - 7:10 pm | Frederick Wittke (Debiopharm International SA, Switzerland) "Debi0 1450: A New Antimicrobial Agent Specifically Targeting Complicated Staphylococcal Infections" |
7:10 pm - 7:20 pm | Discussion |
7:20 pm - 7:50 pm | Roger Echols (Shionogi Inc., USA) "Stumbling Towards Approval of a Pathogen-Focused Antibiotic: The Story of S-649266, a Siderophore Cephalosporin" |
7:50 pm - 8:00 pm | Discussion |
8:00 pm | Dinner |
Thursday |
7:30 am - 8:30 am | Breakfast |
8:30 am - 9:00 am | Business Meeting |
| Nominations for the Next Vice Chair; Fill in Conference Evaluation Forms; Discuss Future Site and Scheduling Preferences; Election of the Next Vice Chair |
9:00 am - 12:30 pm | Alternative Mechanisms of Action and Antibacterial Modalities |
| This session will focus on non-traditional approaches to antibacterial drugs, including novel combination approaches. |
| Discussion Leader: Robert Hancock (University of British Columbia, Canada) |
9:00 am - 9:05 am | Introduction by Discussion Leader |
9:05 am - 9:40 am | Man-Wah Tan (Genentech Inc, USA) "Antibody-Antibiotic Conjugate for Treatment of Bacterial Infections" |
9:40 am - 9:50 am | Discussion |
9:50 am - 10:25 am | Cristina Landeta (Harvard Medical School, USA) "Targeting Disulfide Bond Formation in Bacteria" |
10:25 am - 10:35 am | Discussion |
10:35 am - 11:00 am | Coffee Break |
11:00 am - 11:35 am | Aileen Rubio (Spero Therapeutics, USA) "Disarming P. aeruginosa Through Inhibition of MvfR" |
11:35 am - 11:45 am | Discussion |
11:45 am - 11:55 am | Selected from Poster Abstracts: Mark Broenstrup (Helmholtz Centre for Infection Research, Germany) "Induction and Quantification of Small Molecule Uptake into Gram-Negative Bacteria" |
11:55 am - 12:00 pm | Discussion |
12:00 pm - 12:10 pm | Selected from Poster Abstracts: Renee Bouley (University of Notre Dame, USA) "Exploration of the Mechanism of Action and Structure-Activity Relationship for a New Class of Quinazolinone Antibiotics" |
12:10 pm - 12:15 pm | Discussion |
12:15 pm - 12:30 pm | Poster Previews |
12:30 pm | Lunch |
1:30 pm - 4:30 pm | Free Time |
4:30 pm - 6:00 pm | Poster Session |
6:00 pm - 8:00 pm | The Future of Antibacterial Diagnostics: How Will New Diagnostics Enable Clinical Trial Design and Clinical Use of New Antibacterials? |
| Discussion Leader: Herman Goossens (University Hospital Antwerp, Belgium) |
6:00 pm - 6:05 pm | Introduction by Discussion Leader |
6:05 pm - 6:35 pm | Linda Miller (GlaxoSmithKline, USA) "Precision Medicine and Diagnostics: Trade-Offs, Challenges, and Opportunities" |
6:35 pm - 6:45 pm | Discussion |
6:45 pm - 7:10 pm | David Ecker (Ibis Biosciences (Abbott), USA) "Solutions to Enrolling the Right Patients: Portable Diagnostics" |
7:10 pm - 7:20 pm | Discussion |
7:20 pm - 7:50 pm | Debra Goff (Ohio State University Wexner Medical Center, USA) "From the Frontline: How Clinicians Apply New Diagnostics Tests" |
7:50 pm - 8:00 pm | Discussion |
8:00 pm | Dinner |
Friday |
7:30 am - 8:30 am | Breakfast |
9:00 am | Departure |